The metabolism of 17α-ethynyloestradiol was studied in one man and 16 women. After intravenous or oral administration, 22·6–46·9% of the dose was excreted in the urine over a 5-day period. Up to 36% of the urinary radioactivity may be present in the unconjugated form with a further 64% being extractable after enzymic hydrolysis. Sulphate conjugates formed only 11·4% of the urinary radioactivity. Semi-quantitation of these extracts showed ethynyloestradiol itself to be the major metabolite, accounting for 3·2–8·4% of the administered dose in the unconjugated fraction with a further 2·4–16·5% in the enzyme hydrolysed fraction. Up to 16·5% of the dose was therefore excreted unchanged, and metabolites less and more polar than ethynyloestradiol were also found. Excretion via the faeces accounted for up to 30% of the administered dose, with most of the extractable radioactivity being in the unconjugated form. Ethynyloestradiol accounted for up to 29·6% of faecal radioactivity. No significant amounts of radioactivity were detected in sweat collected from one subject 2 or 24 h after administration of the dose. Plasma levels of 3·32% and 1·72% of the administered dose per litre were found 1 and 24 h after administration. Metabolites in plasma were present mainly as sulphate conjugates.
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
Sept 2018 onwards | Past Year | Past 30 Days | |
---|---|---|---|
Full Text Views | 4 | 3 | 0 |
PDF Downloads | 9 | 4 | 0 |